Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations-Reference-Cited by-同舟云学术

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Published:2019-03-29 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Ascierto Paolo A.,Capone Mariaelena,Grimaldi Antonio M.,Mallardo Domenico,Simeone Ester,Madonna Gabriele,Roder Heinrich,Meyer Krista,Asmellash Senait,Oliveira Carlos,Roder Joanna,Grigorieva Julia^ORCID

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0569-1.pdf

Reference24 articles.

1. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–51.

2. Long GV, Weber JS, Infante JR, et al. Overall survival and durable responses in patients with BRAF V600–mutant metastatic melanoma receiving Dabrafenib combined with Trametinib. J Clin Oncol. 2016;34:871–8.

3. Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315–27.

4. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018.

5. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853–62.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?;Pharmacology & Therapeutics;2024-04

2. Efficacy of immunotherapy in patients with metastatic melanoma;Meditsinskiy sovet = Medical Council;2024-01-19

3. Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma;Cancers;2023-09-03

4. Prospective on Imaging Mass Spectrometry in Clinical Diagnostics;Molecular & Cellular Proteomics;2023-09

5. Data-driven analysis to identify prognostic immune-related biomarkers in BRAF mutated cutaneous melanoma microenvironment;Frontiers in Genetics;2022-11-30